Aromatase inhibitors and their future role in post-menopausal women with early breast cancer

British Journal of Cancer

Volumn 78, Issue SUPPL. 4, 1998, Pages 12-15

  Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adjuvant; Anastrozole; Aromatase inhibitors; Early breast cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; FORMESTANE; LIPID; MEGESTROL ACETATE; PARTIAL AGONIST; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; LIPID BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 0031717237     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.756     Document Type: Article

References (25)

1. Baum M and Houghton J (1998) Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer (abstract P99). Eur J Cancer 34(suppl. 1): S39
2. Buzdar A, Jonat W and Howell A (1996a) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000-2011
3. Buzdar AU, Howell A, Jones S, Blomqvist C, Vogel C, Eirman W, Wolters J, Mauriac L, Eisenberg P, Jonat W, Plourde P and Azab M (1996b) Prolonged exposure confirms a favorable tolerability profile of Arimidex (anastrozole) as compared to megestrol acetate (MA) from two large randomised trials in postmenopausal women with advanced breast cancer (ABC) (abstract 100). Proc Am Soc Clin Oncol 15: 109
4. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P and Webster A (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739
5. Coombes RC, Powles TJ, Easton D, Chilvers C, Ford HT, Smith IE, McKinna A, White H, Bradbeer J, Yarnold J, Nash A, Bettelheim R, Dowsett M and Gazet JC (1987) Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res 47: 2496-2499
6. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group (1996) Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged 50 years or older with breast cancer. J Natl Cancer Inst 88: 1834-1839
7. Dombernowsky P, Smith I, Falkson G, et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461
8. Dowsett M, Tobias JS, Howell A, Blackman GM, Welch H, King N, Ponzone R, von Euler M and Baum M (1998) The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br J Cancer (in press)
9. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85
10. Fisher B, Dignam J, Bryant J, et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542
11. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO and Lønning PE (1996a) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 74: 1286-1291
12. Geisler J, Johannessen DC, Anker G and Lønning PE (1996b) Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur J Cancer 32A: 789-792
13. Geisler J, Lien EA, Ekse D and Lønning PE (1997) Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 63: 53-58
14. Jonat W, Howell A, Blomqvist C, et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404-421
15. Jones S, MacNeill FA, Jacobs S, Lønning PE, Dowsett M and Powles TJ (1992) The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28A: 1712-1716
16. Lien EA, Anker G, Lønning PE, Solheim E and Ueland PM (1990) Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50: 5851-5857
17. Lønning PE (1996) Pharmacology of new aromatase inhibitors. Breast 5: 202-208
18. Lundgren S, Helle SI and Lønning PE (1996) Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 2: 1515-1521
19. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ and Dowsett M (1992) The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66: 692-697
20. Pannuti F, Martoni A, Cilenti G, Camaggi CM and Fruet F (1988) Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 24: 423-429
21. Roseman BJ, Buzdar AU and Singletary SE (1997) Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol 66: 215-220
22. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549
23. Tominaga T, Yoshida Y, Shimozuma K, Hayashi K and Kosaki G (1990) Effect of CGS 16949 A plus tamoxifen on induced mammary tumours in rats. Eur J Cancer 26: 600-603
24. Yates RA, Dowsett M, Fisher GV, Selen A and Wyld PJ (1996) Arimidex (ZD1033): a selective, potent inhibitor of aromatase in post-menopausal female volunteers. Br J Cancer 73: 543-548
25. Zaccheo T, Giudici D and Di Salle E (1993) Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol 44: 677-680